MOH

PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101

Retrieved on: 
Tuesday, April 23, 2024
NDA, African trypanosomiasis, MOH, IBN, Trypanosoma brucei, Physician, Ministry, DSM-IV codes, Government, Trypanosomiasis

The request seeks emergency access to the Company’s recently completed registration batches of PAX-101 (IV suramin) to address the critical shortage of medications required to combat the life-threatening sleeping sickness, also known as Trypanosoma brucei rhodesiense, Human African trypanosomiasis (TBr HAT), crisis in the region.

Key Points: 
  • The request seeks emergency access to the Company’s recently completed registration batches of PAX-101 (IV suramin) to address the critical shortage of medications required to combat the life-threatening sleeping sickness, also known as Trypanosoma brucei rhodesiense, Human African trypanosomiasis (TBr HAT), crisis in the region.
  • Howard Weisman, Chairman and CEO of PaxMedica, emphasized the Company's dedication to providing immediate assistance in light of the urgent situation, stating: "The emergency request from the Ministry of Health of Malawi underscores the critical need for IV suramin to combat the continued devastating impact of sleeping sickness in the region.
  • PaxMedica has worked diligently for many years to ensure access to this life-saving medication for those in need and today’s response to an urgent crisis strongly demonstrates our commitment to this mission."
  • The decision comes in the wake of PaxMedica's recent completion of three pivotal registration/validation batches of PAX-101 ( PaxMedica - A Promising Path in Autism ), as part of its ongoing development program.

PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness

Retrieved on: 
Tuesday, April 16, 2024
FDA, Public, NDA, Food, Trial of the century, Neglected tropical diseases, MOH, IBN, Trypanosoma brucei, Patient, Incidence, Ministry, DSM-IV codes, Priority review, Infection, Standard of care, Real World, Ministry (collective executive), TBR, Suramin, Pharmaceutical industry

TARRYTOWN, New York, April 16, 2024 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica , Inc. (NASDAQ: PXMD ), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced it has received an urgent request from the Ministry of Health (MOH) of Malawi, asking for emergency access to IV suramin to avert a potential humanitarian crisis brought on by dwindling supplies of drugs used routinely to save lives in that region of Africa.

Key Points: 
  • TARRYTOWN, New York, April 16, 2024 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica , Inc. (NASDAQ: PXMD ), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced it has received an urgent request from the Ministry of Health (MOH) of Malawi, asking for emergency access to IV suramin to avert a potential humanitarian crisis brought on by dwindling supplies of drugs used routinely to save lives in that region of Africa.
  • PaxMedica, which just last week announced that it has completed execution of its three pivotal registration/validation batches of PAX-101 (an IV form of suramin), has brought this emergency request to the attention of the U.S. Food and Drug Administration (FDA) to determine potential impact, if any, on the ongoing development program and NDA submission plans for PAX-101.
  • PaxMedica has previously announced the completion of its recent Type B meeting with FDA in preparation for submitting an NDA for the use of PAX-101 in the treatment of the rare and fatal trypanosomal infection, Trypanosoma brucei rhodesiense, caused by the bite of a tsetse fly.
  • ( PaxMedica - A Promising Path in Autism ) “Having the highest incidence of TBr HAT in the world, the Malawi Ministry of Health enabled PaxMedica to conduct the first and only analysis of efficacy in the actual setting where historically the vast majority of these infections have been successfully treated”, said Weisman.

Kitchen Brains Empowers Appliance OEMs with MoH™ Innovation: Liz Spina Joins the Team

Retrieved on: 
Friday, April 5, 2024
MOH, Culture, Syracuse University, Business development, Original equipment manufacturer, History, OEM, Restaurant

This strategic move reinforces Kitchen Brains' unwavering dedication to empowering Original Equipment Manufacturers (OEMs) in the commercial kitchen space and driving the future of Middle of House™ (MoH) connected kitchen technology.

Key Points: 
  • This strategic move reinforces Kitchen Brains' unwavering dedication to empowering Original Equipment Manufacturers (OEMs) in the commercial kitchen space and driving the future of Middle of House™ (MoH) connected kitchen technology.
  • "That's why our strategy centers on partnering with leading appliance OEMs and enabling Korrect Technology in every appliance.
  • "I am thrilled to join the Kitchen Brains team where we foster a culture of technical industry leadership and customer excellence," says Liz Spina.
  • Kitchen Brains remains committed to being a trusted partner for OEMs navigating the rapidly evolving landscape of commercial kitchen technology.

Kitchen Brains Empowers Appliance OEMs with MoH™ Innovation: Liz Spina Joins the Team

Retrieved on: 
Friday, April 5, 2024
MOH, Culture, Syracuse University, Business development, Original equipment manufacturer, History, OEM, Restaurant

This strategic move reinforces Kitchen Brains' unwavering dedication to empowering Original Equipment Manufacturers (OEMs) in the commercial kitchen space and driving the future of Middle of House™ (MoH) connected kitchen technology.

Key Points: 
  • This strategic move reinforces Kitchen Brains' unwavering dedication to empowering Original Equipment Manufacturers (OEMs) in the commercial kitchen space and driving the future of Middle of House™ (MoH) connected kitchen technology.
  • "That's why our strategy centers on partnering with leading appliance OEMs and enabling Korrect Technology in every appliance.
  • "I am thrilled to join the Kitchen Brains team where we foster a culture of technical industry leadership and customer excellence," says Liz Spina.
  • Kitchen Brains remains committed to being a trusted partner for OEMs navigating the rapidly evolving landscape of commercial kitchen technology.

Koning Health Achieves UAE Regulatory Clearance, Paving the Way for Breast CT Commercialization in the Middle East

Retrieved on: 
Wednesday, February 28, 2024
Woman, Ministry, MOH, Female, Growth, Perseverance, Ministry of Health, FANR, MEA, Medical imaging

Maher Bannourah, Director of Koning International, led the initiative by leveraging his industry experience with Ministry of Health (MOH) representatives.

Key Points: 
  • Maher Bannourah, Director of Koning International, led the initiative by leveraging his industry experience with Ministry of Health (MOH) representatives.
  • This regulatory approval positions Koning as the first company to introduce breast CT technology in the UAE, setting a new standard in breast imaging and care in the region.
  • "Koning is honored to be accepted as the only approved breast CT in the UAE.
  • The company is excited to embark on this new chapter of growth and innovation in the UAE and beyond.

Italy Compact Construction Equipment Market Assessment 2023-2029: Caterpillar, Volvo CE, Komatsu, JCB, CNH Industrial, SANY, and Hitachi Lead with Strong Market Share and Diverse Equipment Offers

Retrieved on: 
Tuesday, January 9, 2024
Lithium, Bed, Wind, Electricity, Government, National Institute of Statistics, Carbon, EIB, CNH Industrial, Energy, Growth, CO2, City, Volvo, MOH, Brenner Base Tunnel, Caterpillar, Mundi, Octopus Energy, Leonardo da Vinci–Fiumicino Airport, Housing, Komatsu, JCB, Hydrogen, MIMIS, Hospital, Plant, Ministry, Rail transport by country, M4, Natural gas, Environment, Metro, Coal, Hitachi Construction Machinery, USD, Red Circle, Infrastructure, Internet of things, Renewable energy

The Italy compact construction equipment market is expected to grow at a CAGR of 4.89% from 2022 to 2029.

Key Points: 
  • The Italy compact construction equipment market is expected to grow at a CAGR of 4.89% from 2022 to 2029.
  • In addition, the growth in renovation and road construction projects is expected to drive the demand for compact earthmoving equipment in the Italy compact construction equipment market.
  • Caterpillar, Volvo CE, Komatsu, JCB, CNH Industrial, SANY, and Hitachi Construction Machinery are front runners in the Italy compact construction equipment market.
  • Compact forklifts accounted for the Italy compact construction equipment market's largest market in 2022.

Arch Biopartners Receives Approval from the Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Retrieved on: 
Wednesday, January 3, 2024
Liver, Arch, AKI, Risk, Reperfusion, IRI, Prevalence, Disease, Mortality, TMX Group, Science Advances, Inflammation, National Research Council, Oxygen, Acute kidney injury, OTCQB, CABG, Ministry, Health Canada, Kidney, Injury, Patient, Ischemia, MOH, Pharmaceutical industry

TORONTO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it has received approval in Turkey from the Ministry of Health to proceed with a Phase II trial for LSALT peptide, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).

Key Points: 
  • TORONTO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it has received approval in Turkey from the Ministry of Health to proceed with a Phase II trial for LSALT peptide, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).
  • LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.
  • With the Ministry of Health (MoH) approval for the trial, Arch can now proceed to contract and activate clinical sites in Turkey.
  • Once blood flow is restored to normal (reperfusion), inflammation is triggered and injury to kidney cells is exacerbated.

Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

Retrieved on: 
Thursday, December 21, 2023
Clinical trial, Liver, Arch, AKI, Conlon, Reperfusion, Risk, IRI, Prevalence, Ethics, Disease, Mortality, TMX Group, Science Advances, Cardiopulmonary bypass, Inflammation, CPB, Renal replacement therapy, National Research Council, Oxygen, Acute kidney injury, OTCQB, CABG, MOH, Health Canada, Kidney, Injury, Patient, Ischemia, Dialysis, Pharmaceutical industry

LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.

Key Points: 
  • LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.
  • The ethics committee approval of the trial will be followed by a final regulatory review conducted by the Turkish Ministry of Health (MoH), expected to be completed by mid-January.
  • Once the trial is approved by the MoH, activation of clinical sites in Turkey will take place and patient enrollment can begin in February.
  • Quote from Richard Muruve, CEO of Arch Biopartners Inc:
    “We look forward to a positive decision from the MoH, which will permit enrollment of Turkish cardiac surgery patients into the trial.

Lunit to Advance Singapore's Healthcare System with AI-powered Solution for Medical Imaging

Retrieved on: 
Thursday, November 30, 2023
Ministry, Health, CGH, Hospital, Bed, MOH, Patient, Medical imaging, Algorithm, SGH, National health insurance, Therapy, Singapore General Hospital, INSIGHT, Diagnosis, NTT DATA, SingHealth, Health care, Changi General Hospital, AI, NTT, Ministry of Health, Medical device, Nursing, Innovation

As part of the agreement, Lunit collaborated with CARPL to provide NTT DATA with Lunit INSIGHT CXR.

Key Points: 
  • As part of the agreement, Lunit collaborated with CARPL to provide NTT DATA with Lunit INSIGHT CXR.
  • AimSG allows public healthcare institutions to integrate AI imaging solutions, like Lunit INSIGHT CXR, seamlessly into their existing clinical radiology workflow, enhancing medical professionals' diagnostic capabilities and efficiency.
  • Healthcare institutions that have adopted Lunit's AI solution through AimSG have had a positive response and are looking forward to improving the medical imaging workflow.
  • "The AimSG platform enables clinicians from public healthcare institutions to deploy AI algorithms to help them deliver better healthcare to the population.

Knight Therapeutics Reports Third Quarter 2023 Results

Retrieved on: 
Thursday, November 9, 2023
DLBCL, Research, MOH, ANVISA, Bank, Lenalidomide, FGFR2, S&M, Thrombocytopenia, LATAM, Health maintenance organization, Fostamatinib, EBITDA, G&A, News, R, ASCT, Hallmark-Sonali Bank Loan Scam, Growth, IAS, Marketing, ITP, USD, Investment, Patient, GBT, Lymphoma, Financial adviser, Pharmaceutical industry, Fine chemical, Bookkeeping, Cryptocurrency, Knight, Novartis, Bancolombia

Gross margin: For the quarter ended September 30, 2023, gross margin, as a percentage of revenues, was 49% compared to 42% in Q3-22.

Key Points: 
  • Gross margin: For the quarter ended September 30, 2023, gross margin, as a percentage of revenues, was 49% compared to 42% in Q3-22.
  • Selling and marketing (“S&M”): For the quarter ended September 30, 2023, S&M expenses were $11,924, a decrease of $1,532 or 11%, compared to the same period in prior year.
  • General and administrative (“G&A”): For the quarter ended September 30, 2023, G&A expenses were $11,080, an increase of $664 or 6%, compared to the same period in prior year.
  • For the quarter ended September 30, 2023, interest income was $3,055, an increase of $593 or 24%, compared to the same period in prior year.